Psychosis is an often-challenging complication of Parkinson’s disease. Neurologist Dr Daniel Claassen and Psychiatrist Dr Gregory Pontone will take you through an interactive patient simulation, sharing their approaches to the management of a more complex patient. You will follow this patient over the course of a few years as her disease progresses and decide on the optimal paths to take in making her diagnosis and recommending treatment. You will learn about the latest guidelines and evidence underlying current best practice.
Navigating Complex Patients with Parkinson’s Disease Psychosis
close0.75 credits
30-45 minutes
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
Details
Presenters
Overview
Disclosure of Conflicts of Interest
Disclosure Policy
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.Faculty
Daniel Claassen, MD, is a consultant for Alterity Therapeutics and Spark Therapeutics, Inc; and is a contracted researcher for Alterity Therapeutics and, CHDI Foundation, Inc, F. Hoffman-La Roche Ltd, Genentech, Inc, Prilenia Therapeutics, and Vaccinex Inc.Gregory Pontone, MD, MHS, is a consultant for ACADIA Pharmaceuticals Inc and Cerevance.
Peer Reviewer
This activity was peer reviewed. The peer reviewer has no relevant financial relationships.Planners and Managers
MedEdicus planners and managers have no relevant commercial relationships to disclose.Target Audience
This activity intends to educate neurologists, psychiatrists, and primary care clinicians caring for patients with PDP.
Learning Objectives
After completing this activity, participants will be better able to:
- Integrate routine screening for symptoms of psychosis in patients with PD into practice
- Develop individualized, evidence-based care plans for persons with PDP
Accreditation and Credit Designation Statements
For Physicians:
Accreditation Statement
MedEdicus LLC is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.For Nurses:
Interprofessional Joint Accreditation Statement
In support of improving patient care, Amedco is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Nursing Credit
The maximum number of hours awarded for this Continuing Nursing Education Activity is 0.75 contact hour.Disclaimer
Instructions for Obtaining Credit
To obtain CME/CE credit for this activity, please listen to the podcast, consult referenced sources as necessary, and complete the posttest and evaluation online. Upon passing, a certificate will be made available immediately.Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or ACADIA Pharmaceuticals Inc.This CME activity is copyrighted to MedEdicus LLC ©2021. All rights reserved. 261.2
Provider(s)/Educational Partner(s)
This continuing medical education activity is provided by MedEdicus LLC.
For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.
To view the MedEdicus Privacy Policy, click here.
Commercial Support
This continuing medical education activity is supported through an educational grant from ACADIA Pharmaceuticals Inc.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
Recommended
Details
Presenters
Overview
Psychosis is an often-challenging complication of Parkinson’s disease. Neurologist Dr Daniel Claassen and Psychiatrist Dr Gregory Pontone will take you through an interactive patient simulation, sharing their approaches to the management of a more complex patient. You will follow this patient over the course of a few years as her disease progresses and decide on the optimal paths to take in making her diagnosis and recommending treatment. You will learn about the latest guidelines and evidence underlying current best practice.
Disclosure of Conflicts of Interest
Disclosure Policy
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.Faculty
Daniel Claassen, MD, is a consultant for Alterity Therapeutics and Spark Therapeutics, Inc; and is a contracted researcher for Alterity Therapeutics and, CHDI Foundation, Inc, F. Hoffman-La Roche Ltd, Genentech, Inc, Prilenia Therapeutics, and Vaccinex Inc.Gregory Pontone, MD, MHS, is a consultant for ACADIA Pharmaceuticals Inc and Cerevance.
Peer Reviewer
This activity was peer reviewed. The peer reviewer has no relevant financial relationships.Planners and Managers
MedEdicus planners and managers have no relevant commercial relationships to disclose.Target Audience
This activity intends to educate neurologists, psychiatrists, and primary care clinicians caring for patients with PDP.
Learning Objectives
After completing this activity, participants will be better able to:
- Integrate routine screening for symptoms of psychosis in patients with PD into practice
- Develop individualized, evidence-based care plans for persons with PDP
Accreditation and Credit Designation Statements
For Physicians:
Accreditation StatementMedEdicus LLC is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.For Nurses:
Interprofessional Joint Accreditation StatementIn support of improving patient care, Amedco is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Nursing Credit
The maximum number of hours awarded for this Continuing Nursing Education Activity is 0.75 contact hour.Disclaimer
Instructions for Obtaining Credit
To obtain CME/CE credit for this activity, please listen to the podcast, consult referenced sources as necessary, and complete the posttest and evaluation online. Upon passing, a certificate will be made available immediately.Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or ACADIA Pharmaceuticals Inc.This CME activity is copyrighted to MedEdicus LLC ©2021. All rights reserved. 261.2
Provider(s)/Educational Partner(s)
This continuing medical education activity is provided by MedEdicus LLC.
For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.
To view the MedEdicus Privacy Policy, click here.
Commercial Support
This continuing medical education activity is supported through an educational grant from ACADIA Pharmaceuticals Inc.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?